- Home
- DB vs ARGX Comparison
DB vs ARGX Comparison
Compare DB & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DB
- ARGX
- Stock Information
- Founded
- DB 1870
- ARGX 2008
- Country
- DB Germany
- ARGX Netherlands
- Employees
- DB N/A
- ARGX N/A
- Industry
- DB Major Banks
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DB Finance
- ARGX Health Care
- Exchange
- DB Nasdaq
- ARGX Nasdaq
- Market Cap
- DB 54.0B
- ARGX 44.2B
- IPO Year
- DB N/A
- ARGX 2017
- Fundamental
- Price
- DB $37.16
- ARGX $756.38
- Analyst Decision
- DB Sell
- ARGX Strong Buy
- Analyst Count
- DB 2
- ARGX 19
- Target Price
- DB N/A
- ARGX $765.72
- AVG Volume (30 Days)
- DB 2.5M
- ARGX 371.7K
- Earning Date
- DB 10-22-2025
- ARGX 10-30-2025
- Dividend Yield
- DB 1.52%
- ARGX N/A
- EPS Growth
- DB 91.11
- ARGX N/A
- EPS
- DB 3.17
- ARGX 18.75
- Revenue
- DB $35,316,500,295.00
- ARGX $3,120,821,000.00
- Revenue This Year
- DB $12.80
- ARGX $80.01
- Revenue Next Year
- DB $2.59
- ARGX $30.64
- P/E Ratio
- DB $11.06
- ARGX $36.10
- Revenue Growth
- DB 12.10
- ARGX 88.04
- 52 Week Low
- DB $15.57
- ARGX $510.06
- 52 Week High
- DB $37.55
- ARGX $779.03
- Technical
- Relative Strength Index (RSI)
- DB 67.44
- ARGX 74.29
- Support Level
- DB $34.77
- ARGX $745.82
- Resistance Level
- DB $35.56
- ARGX $779.03
- Average True Range (ATR)
- DB 0.54
- ARGX 15.99
- MACD
- DB -0.03
- ARGX 2.76
- Stochastic Oscillator
- DB 88.45
- ARGX 78.32
About DB Deutsche Bank AG
Deutsche Bank is a universal bank operating on a global scale. The bank offers corporate, retail, investment banking, private banking, and asset management to its clients.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.